scholarly journals EPWORTH SLEEPINESS SCALE: A SCREENING TOOL FOR PATIENTS WITH SLEEP DISORDERED BREATHING

CHEST Journal ◽  
2021 ◽  
Vol 160 (4) ◽  
pp. A2440
Author(s):  
Sarang Patil
2020 ◽  
Vol 2020 ◽  
pp. 1-6 ◽  
Author(s):  
Yi Rong ◽  
Shihan Wang ◽  
Hui Wang ◽  
Feng Wang ◽  
Jingjing Tang ◽  
...  

Background. There is a growing number of patients with sleep-disordered breathing (SDB) referred to sleep clinics. Therefore, a simple but useful screening tool is urgent. The NoSAS score, containing only five items, has been developed and validated in population-based studies. Aim. To evaluate the performance of the NoSAS score for the screening of SDB patients from a sleep clinic in China, and to compare the predictive value of the NoSAS score with the STOP-Bang questionnaire. Methods. We enrolled consecutive patients from a sleep clinic who had undergone apnea-hypopnea index (AHI) testing by type III portable monitor device at the hospital and completed the STOP-Bang questionnaire. The NoSAS score was assessed by reviewing medical records. Sensitivity, specificity, positive predictive value, negative predictive value, and area under the receiver operating characteristic curve (AUC) of both screening tools were calculated at different AHI cutoffs to compare the performance of SDB screening. Results. Of the 596 eligible patients (397 males and 199 female), 514 were diagnosed with SDB. When predicting overall (AHI ≥ 5), moderate-to-severe (AHI ≥ 15), and severe (AHI ≥ 30) SDB, the sensitivity and specificity of the NoSAS score were 71.2, 80.4, and 83.1% and 62.4, 49.3, and 40.7%, respectively. At all AHI cutoffs, the AUC ranged from 0.688 to 0.715 for the NoSAS score and from 0.663 to 0.693 for the STOP-Bang questionnaire. The NoSAS score had the largest AUC (0.715, 95% CI: 0.655–0.775) of diagnosing SDB at AHI cutoff of ≥5 events/h. NoSAS performed better in discriminating moderate-to-severe SDB than STOP-Bang with a marginally significantly higher AUC (0.697 vs. 0.663, P=0.046). Conclusion. The NoSAS score had good performance on the discrimination of SDB patients in sleep clinic and can be utilized as an effective screening tool in clinical practice.


2016 ◽  
Vol 20 (4) ◽  
pp. 1225-1230 ◽  
Author(s):  
K. Kanabar ◽  
S. K. Sharma ◽  
V. Sreenivas ◽  
A. Biswas ◽  
M. Soneja

Author(s):  
Dhruva Chaudhry ◽  
Debraj Jash ◽  
Savita Singhal ◽  
Manjunath B G ◽  
Jaikrit Bhutani ◽  
...  

PLoS ONE ◽  
2014 ◽  
Vol 9 (11) ◽  
pp. e112959 ◽  
Author(s):  
Ainara Garde ◽  
Parastoo Dehkordi ◽  
Walter Karlen ◽  
David Wensley ◽  
J. Mark Ansermino ◽  
...  

2011 ◽  
Vol 07 (05) ◽  
pp. 467-472 ◽  
Author(s):  
Graciela E. Silva ◽  
Kimberly D. Vana ◽  
James L. Goodwin ◽  
Duane L. Sherrill ◽  
Stuart F. Quan

2000 ◽  
Vol 122 (3) ◽  
pp. 387-394 ◽  
Author(s):  
Sean C. Coleman ◽  
Timothy L. Smith

This study is a prospective, nonrandomized clinical trial initiated to assess the safety and efficacy of radiofrequency tissue reduction of the palate for the treatment of bothersome snoring and sleep-disordered breathing. Twelve healthy volunteers with socially disruptive snoring underwent a baseline polysomnogram along with a battery of visual analog scales (VASs) to measure daytime sleepiness, snoring level, pain, and disturbances of speech and swallowing. After radiofrequency tissue reduction of the palate, they were re-evaluated with a mean follow-up after the final procedure of 15.7 ± 5.1 (mean ± SD) weeks. As rated by the bed partner, a significant reduction in the level of snoring occurred in all 12 patients, with a mean pretreatment snoring level of 8.3 ± 2.1 to a mean posttreatment snoring level of 2.1 ± 1.4. (Student t test, P < 0.0001) These patients required an average of 2.3 treatment sessions each. Nine of 12 had a reduction in snoring from a bothersome level (VAS range 5–10) to a nonbothersome level (VAS range 0–3). Daytime sleepiness as measured by the Epworth Sleepiness Scale (0–24) decreased from 10.8 ± 4.4 to 8.3 ± 4.1 ( P = 0.011). Posttreatment pain was considered absent or minimal in 11 of 12 patients and was managed with acetaminophen. No significant adverse events or complications were reported.


Sign in / Sign up

Export Citation Format

Share Document